Connecticut Chronicle

Hemophilia B Analysis, Market Size, Epidemiology, Leading Companies and Competitive Analysis By DelveInsight

 Breaking News
  • No posts were found

Hemophilia B Analysis, Market Size, Epidemiology, Leading Companies and Competitive Analysis By DelveInsight

April 02
17:56 2020
Hemophilia B Analysis, Market Size, Epidemiology, Leading Companies and Competitive Analysis By DelveInsight

DelveInsight has launched a new report on Hemophilia B Market Insights, Epidemiology and Market Forecast-2030

DelveInsight’s “Hemophilia B – Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Hemophilia B, historical and forecasted epidemiology as well as the Hemophilia B market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Hemophilia B market report provides current treatment practices, emerging drugs, Hemophilia B market share of the individual therapies, current and forecasted Hemophilia B market Size from 2017 to 2030 segmented by seven major markets. The Report also covers current Hemophilia B treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.

According tothe Centers for Disease Control and Prevention, Hemophilia B is a genetic disorder caused by missing or defective Factor IX clotting protein. With the lack of this, the blood cannot clot properly to control bleedinglike hemophilia A, it is also inherited and is caused by a spontaneous genetic mutation in one-third of the cases. Individuals with hemophilia B do not bleed faster than unaffected individuals, they bleed longer.

 

Request for :- free sample page

Epidemiology

The Hemophilia B epidemiology division provide insights about historical and current Hemophilia B patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken. 

Reports Key facts:- 

1.  According to the World Federation of Hemophilia (WFH), the total number of cases around the World for Hemophilia B in 2018 was 34,289.

2. Centers for Disease Control and Preventionstates Hemophilia occurs in about 1 of every 5,000 male births and Hemophilia A is about four times as common as hemophilia B, and about half of those affected have a severe form. Hemophilia affects people from all racial and ethnic groups. Additionally about 3 in 100 people with hemophilia B develop an inhibitor to the treatment product used to treat or prevent their bleeding episodes.

3. As per Santoro, Cristina, et al., 2018, the development of an inhibitor in Hemophilia B is a rare event i.e., 1.5–3% of all patients but is associated with a significant morbidity, related not only to the bleeding risk but also to the frequent occurrence of allergic reactions and nephrotic syndrome.

Key companies working on Hemophilia B that are given below:-

1.  Novo Nordisk Pharma Co.

2.  CSL Behring Pharma Co. 

3.  Bioverativ Therapeutics (a Sanofi acquired company)

Drug names are given below:- 

1. Rebinyn

2. Idelvion

3. Alprolix

Table of contents

1. Key Insights

2. Executive Summary of Hemophilia B

3. Competitive Intelligence Analysis for Hemophilia B

4. Hemophilia B: Market Overview at a Glance

4.1. Hemophilia B Total Market Share (%) Distribution in 2017

4.2. Hemophilia B Total Market Share (%) Distribution in 2030

5. Hemophilia B: Disease Background and Overview

5.1. Introduction

5.2. Sign and Symptoms 

5.3. Pathophysiology 

5.4. Risk Factors 

5.5. Diagnosis 

6. Patient Journey

7. Hemophilia B Epidemiology and Patient Population

7.1. Epidemiology Key Findings

7.2. Assumptions and Rationale: 7MM

7.3. Epidemiology Scenario: 7MM

7.3.1. Hemophilia B Epidemiology Scenario in the 7MM (2017-2030)

7.4. United States Epidemiology

7.4.1. Hemophilia B Epidemiology Scenario in the United States (2017-2030)

7.5. EU-5 Country-wise Epidemiology

7.5.1. Germany Epidemiology

7.5.1.1. Hemophilia B Epidemiology Scenario in Germany (2017-2030)

7.5.2. France Epidemiology

7.5.2.1. Hemophilia B Epidemiology Scenario in France (2017-2030)

7.5.3. Italy Epidemiology

7.5.3.1. Hemophilia B Epidemiology Scenario in Italy (2017-2030)

7.5.4. Spain Epidemiology

7.5.4.1. Hemophilia B Epidemiology Scenario in Spain (2017-2030)

7.5.5. United Kingdom Epidemiology

7.5.5.1. Hemophilia B Epidemiology Scenario in the United Kingdom (2017-2030)

7.5.6. Japan Epidemiology

7.5.6.1. Hemophilia B Epidemiology Scenario in Japan (2017-2030)

8. Treatment Algorithm, Current Treatment, and Medical Practices

8.1. Hemophilia B Treatment and Management

8.2. Hemophilia B Treatment Algorithm 

9. Unmet Needs

10. Key Endpoints of Hemophilia B Treatment

11. Marketed Products

11.1. List of Marketed Products in the 7MM

11.2. Drug Name: Company Name

11.2.1. Product Description

11.2.2. Regulatory Milestones

11.2.3. Other Developmental Activities

11.2.4. Pivotal Clinical Trials

11.2.5. Summary of Pivotal Clinical Trial

List to be continued in report

12. Emerging Therapies

12.1. Key Cross

12.2. Drug Name: Company Name

12.2.1. Product Description

12.2.2. Other Developmental Activities

12.2.3. Clinical Development

12.2.4. Safety and Efficacy

12.2.5. Product Profile

List to be continued in report

13. Hemophilia B: Seven Major Market Analysis

13.1. Key Findings

13.2. Hemophilia B Market Size in 7MM

13.3. Hemophilia B Market Size by Therapies in the 7MM

14. Attribute analysis

15. 7MM: Market Outlook

15.1. United States: Market Size

15.1.1. Hemophilia B Total Market Size in the United States

15.1.2. Hemophilia B Market Size by Therapies in the United States

15.2. EU-5 countries: Market Size and Outlook

15.3. Germany Market Size

15.3.1. Hemophilia B Total Market Size in Germany

15.3.2. Hemophilia B Market Size by Therapies in Germany

15.4. France Market Size

15.4.1. Hemophilia B Total Market Size in France

15.4.2. Hemophilia B Market Size by Therapies in France

15.5. Italy Market Size

15.5.1. Hemophilia B Total Market Size in Italy

15.5.2. Hemophilia B Market Size by Therapies in Italy

15.6. Spain Market Size

15.6.1. Hemophilia B Total Market Size in Spain

15.6.2. Hemophilia B Market Size by Therapies in Spain

15.7. United Kingdom Market Size

15.7.1. Hemophilia B Total Market Size in the United Kingdom

15.7.2. Hemophilia B Market Size by Therapies in the United Kingdom

15.8. Japan Market Outlook

15.8.1. Japan Market Size

15.8.2. Hemophilia B Total Market Size in Japan

15.8.3. Hemophilia B Market Size by Therapies in Japan

16. Access and Reimbursement Overview of Hemophilia B

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

20.1. Bibliography

20.2. Report Methodology

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

Why should you buy this report?

  • The report will help in developing business strategies by understanding trends shaping and driving the Hemophilia B market
  • To understand the future market competition in the Hemophilia B market and Insightful review of the key market drivers and barriers
  • Organize sales and marketing efforts by identifying the best opportunities for Hemophilia B in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
  • Organize sales and marketing efforts by identifying the best opportunities for Hemophilia B market
  • To understand the future market competition in the Hemophilia B market

Related Reports:- 

1. Hemophilia B – Pipeline Insights, 2020

2. Hemophilia A – Pipeline Insights, 2020

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/